Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients

Hemodialysis International

Volumn 14, Issue 4, 2010, Pages 425-432

  Balci, Mustafa ^a   Kirkpantur, Alper ^b   Gulbay, Mutlu ^c   Gurbuz, Oguz Alp ^d  

^a Departments of Cardiology   (Turkey)

^b Nephrology ^*  (Turkey)

^c Radiology   (Turkey)

^d MINISTRY OF HEALTH   (Turkey)

Author keywords

Atherosclerosis; Carotid artery; FGF 23; Hemodialysis

Indexed keywords

ALFACALCIDOL; ANTIHYPERTENSIVE AGENT; CALCIUM ACETATE; CALCIUM CARBONATE; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 23; SEVELAMER; WARFARIN;

ADULT; AGED; ARTICLE; CAROTID ATHEROSCLEROSIS; COMMON CAROTID ARTERY; DOPPLER FLOWMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INTIMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; THICKNESS;

ADULT; AGED; BIOLOGICAL MARKERS; CALCINOSIS; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 77958572969     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00480.x     Document Type: Article

References (31)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974; 290:697-701.
2. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis. 1992; 19:505-513.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie WG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-2218.
4. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005; 16:1788-1793.
5. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67:1179-1187.
6. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348:1656-1663.
7. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001; 86:497-500.
8. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate cotransport activity and 1α, 25-dihydroxyvitamin D3 production. J Biol Chem. 2003; 278:2206-2211.
9. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with endstage renal disease on hemodialysis. Kidney Int. 2004; 65:1943-1946.
10. Gutiérrez OM, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16:2205-2215.
11. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359:584-592.
12. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol. 1993; 4:1205-1213.
13. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42:1206-1252.
14. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation. 1986; 74:1399-1406.
15. Larsson TB. The role of FGF-23 in CKD-MBD and cardiovascular disease: Friend or foe? Nephrol Dial Transplant. 2010; 25:1376-1381.
16. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009; 24:2792-2796.
17. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009; 205:385-390.
18. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009; 24:3125-3131.
19. Inaba M, Okuno S, Imanishi Y, et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006; 17:1506-1513.
20. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119:2545-2552.
21. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: Associated factors and survival consequences. Nephrol Dial Transplant. 2009; 24:948-955.
22. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010; 25:2679-2685.
23. Zoccali C. FGF-23 in dialysis patients: Ready for prime time? Nephrol Dial Transplant. 2009; 24:1078-1081.
24. Nikolov I, Joki N, Drueke T, Massy Z. Beyond phosphate-role of uraemic toxins in cardiovascular calcification. Nephrol Dial Transplant. 2006; 21:3354-3357.
25. Razzaque MS. The FGF23-klotho axis: Endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. 2009; 5:611-619.
26. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem. 1997; 45:1005-1019.
27. Farb A, Lee SJ, Min DH, et al. Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein. Circ Res. 1997; 80:542-550.
28. Agrotis A, Kanellakis P, Kostolias G, et al. Proliferation of neointimal smooth muscle cells after arterial injury. Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9. J Biol Chem. 2004; 279:42221-42229.
29. Lewis CD, Olson NE, Raines EW, Reidy MA, Jackson CL. Modulation of smooth muscle proliferation in rat carotid artery by platelet-derived mediators and fibroblast growth factor-2. Platelets. 2001; 12:352-358.
30. Sigala F, Savvari P, Liontos M, et al. Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NFkappaB pathway. J Cell Mol Med. 2010, doi: DOI: 10.1111/j.1582-4934.2010.01082.x.
31. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444:770-774.